Clinical Trials
31 trialsStudy of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
Mature B-Cell Lymphoma And Leukemia Study III
St. Jude Children's Research Hospital
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Alliance for Clinical Trials in Oncology
H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis
University of New Mexico
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
University Hospital Schleswig-Holstein
LAL1308
Gruppo Italiano Malattie EMatologiche dell'Adulto
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Interfant06
Dutch Childhood Oncology Group
LAL0904
Gruppo Italiano Malattie EMatologiche dell'Adulto
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
Modified MRCUKALLâ…«/ECOGE2993 Regimen for ALL
Sun Yat-sen University
Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
Memorial Sloan Kettering Cancer Center
AIEOP LLA 2000
Associazione Italiana Ematologia Oncologia Pediatrica
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
University Hospital Schleswig-Holstein
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL
Swiss Cancer Institute
Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center